Our Team
Coleen Murphy, PhD
Dr. Murphy is the Director of the Lewis-Sigler Institute for Integrative Genomics and the James A. Elkins, Jr. Professor in the Life Sciences at Princeton University. She also directs the Glenn Foundation for Research on Aging at Princeton and the Simons Collaboration on Plasticity in the Aging Brain. She earned her PhD in Biochemistry from Stanford and completed postdoctoral training at UCSF in the genomics of aging. At Princeton, Dr. Murphy’s lab develops C. elegans models of human quality-of-life aging phenotypes, including cognitive and reproductive aging, and has identified genetic pathways that extend these processes across species. She is the author of How We Age: The Science of Longevity, a 2024 PROSE Finalist. Her honors include the NIH Director’s New Innovator Award, HHMI-Simons Faculty Scholar recognition, and two NIH Director’s Pioneer Awards.
Co-Founder
Trinna Cuellar, PhD, MBA
Dr. Cuellar is a biotech leader and serial entrepreneur with more than 25 years of experience translating complex biology into products and clinical-stage programs. She was on the founding team of Tally Health (acquired), where she helped develop and launch an epigenetic aging clock model and interventions within a year, while authoring five peer-reviewed publications. She previously led 858 Therapeutics’ New York subsidiary/stayed on when Gotham was acquired. The lead asset there has an FDA Fast Track designation. Earlier in her career, Dr. Cuellar discovered drug targets and co-developed widely cited technology platforms at Genentech, publishing in journals including Nature and Cancer Cell. Her expertise spans aging, oncology, CRISPR screening, RNA therapeutics, neurodegeneration, and regenerative medicine. She holds a PhD from UCSF and an MBA from MIT.
Co-Founder and CEO
Rachel Kaletsky, PhD
Dr. Kaletsky graduated from Rutgers University with a B.S. in Biotechnology. She then received her PhD in Cellular & Molecular Biology at the University of Pennsylvania. In her postdoctoral work and current position as Research Scholar working with Dr. Murphy at Princeton, she has worked extensively across multiple aging fields, including neurodegeneration, cognitive aging, and reproductive aging. Her work in the Murphy labs including pioneering several genomics methods in C. elegans for the study of aging, and she carried out the first research on systemic signals for human reproductive aging in blood. Her focus is on molecular technology development, characterizing the molecular mechanisms of aging, and identifying aging interventions.
Co-Founder
Ms. Dobbins graduated from Stanford University with a B.S. in Biomedical Computation and has been researching age-related diseases throughout her academic career. While at Stanford, she studied Huntington’s Disease in the Frydman Lab. After graduation, she worked at Denali Therapeutics on a clinical trial for Amyotrophic Lateral Sclerosis. She is currently a PhD student in Quantitative and Computational Biology at Princeton, where she is co-advised by Dr. Coleen Murphy and Dr. Olga Troyanskaya. Her expertise is the development of machine-learning models, and in the Murphy lab she is currently developing new approaches for incorporation of non-linear information from blood for the study of reproductive aging.
Machine Learning/Model Architect